TABLE 1C.
Patient population characteristics for the six test sets.
| Trial 1 (n = 18) | Trial 2 (n = 18) | Trial 3 (n = 18) | Trial 4 (n = 18) | Trial 5 (n = 18) | Trial 6 (n = 18) | |
| Sex (female, %) | 100% | 89% | 94% | 89% | 100% | 100% |
| Age (mean ± SD) | 34 ± 9 | 46 ± 16 | 41 ± 10 | 47 ± 15 | 38 ± 11 | 37 ± 13 |
| SLE duration (mean ± SD) | 6 ± 7 | 5 ± 6 | 9 ± 10 | 3 ± 5 | 8 ± 8 | 7 ± 8 |
| SLEDAI-2K (mean ± SD) | 2 ± 1 | 1 ± 1 | 2 ± 2 | 2 ± 2 | 3 ± 2 | 3 ± 1 |
| SDI (mean ± SD) | 0.83 ± 0.9 | 1.6 ± 1.5 | 1 ± 1.2 | 0.8 ± 1.3 | 0.7 ± 1.1 | 0.6 ± 0.8 |
Sex, age and SLE clinical variables are described for the population included in each trial. SLEDAI = Systemic Lupus Erythematosus Disease Activity Index 2000. SDI = Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.